There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Plus Therapeutics (PSTV – Research Report) and Biomea Fusion (BMEA – Research Report) with bullish sentiments.
Plus Therapeutics (PSTV)
In a report released today, Justin Walsh from JonesTrading maintained a Buy rating on Plus Therapeutics, with a price target of $71.00. The company’s shares closed last Monday at $3.62, close to its 52-week low of $3.21.
According to TipRanks.com, Walsh has 0 stars on 0-5 stars ranking scale with an average return of
Currently, the analyst consensus on Plus Therapeutics is a Strong Buy with an average price target of $17.00, which is a 345.0% upside from current levels. In a report issued on April 21, H.C. Wainwright also maintained a Buy rating on the stock with a $3.50 price target.
See Insiders’ Hot Stocks on TipRanks >>
Biomea Fusion (BMEA)
In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Biomea Fusion, with a price target of $37.00. The company’s shares closed last Monday at $29.78.
According to TipRanks.com, Pantginis is ranked 0 out of 5 stars with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Biomea Fusion with a $40.17 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on PSTV:
- Plus Therapeutics Announces Reverse Stock Split
- Plus Therapeutics announce reverse stock split
- Plus Therapeutics reports Q1 EPS (14c), consensus (13c)
- Plus Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
- Plus Therapeutics Completes Enrollment of the Original Three Patients Required for Cohort 8 of ReSPECT-GBM Phase 1/2a Trial
